HORMONAL CONTRACEPTION AND PREGNANCY AS SPECIFIC REPRODUCTIVE RISK FACTORS FOR VENOUS THROMBOTIC EVENTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To identify the major confounding factors of primary venous thromboses and embolisms in reproductive- aged women. Subjects and methods. Retrospective analysis of risk factors for venous thromboembolic events (VTEEs) was made in 53 reproductive-aged (18-45-year-old) women with no history of severe somatic diseases and thromboses. Results. In 67.9% of the patients, the major triggers of primary VTEEs were the use of combined oral contraceptive (COC) pills (43.4%) and pregnancy/postpartum (24.5%). The most common cofactors were lower extremity varices (79.2%>), over 35 years of age (62.4%), a sedentary lifestyle (60.4%), smoking (33.9%), obesity (33.9%), and positive family history of thromboses/genetically verified thrombophilia (20.8%). The mean number of background risk factors was 3.4±0.1 in COC users, 3.7+0.2 in pregnant women, and 5.0±0.1 in puerperas. Conclusion. When prescribing COC pills, planning, and managing pregnancy/postpartum, it is necessary to keep in mind that the risk of VTEEs is increased, to thoroughly assess the already existing risk factors, and to take every measure for their prevention.

Full Text

Restricted Access

About the authors

Tatiana Evgen'evna Belokrinitskaya

Chita State Medical Academy, Ministry of Health of Russia

Email: tanbell24@mail.ru
M.D., professor, Chief of the Department of Obstetrics & Gynecology Chita 672090, Gorkiy str. 39a

Nataly Ivanovna Frolova

Chita State Medical Academy, Ministry of Health of Russia

Email: taasyaa@mail.ru
Assistant of Professor, Department of Obstetrics & Gynecology Chita 672090, Gorkiy str. 39a

Evgeny Vladimirovich Galigin

Russia territorial Clinical Hospital

Email: tanbell24@mail.ru
head of the Gynecology Department Chita 672090, Kohansky str. 5

Dmitry Borisovich Nardin

Russia territorial Clinical Hospital

Email: tanbell24@mail.ru
head of the Cardiac Surgery Department Chita 672090, Kohansky str. 5

Evgeny Yur'evich Morozov

Russia town Clinical Hospital One

Email: tanbell24@mail.ru
angiosurgeon doctor of No 2 Surgery Department Chita 672010, Lenina str. 8, Russia

References

  1. ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum. Reprod. Update. 2013; 19(5): 471-82.
  2. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; 4(2-1): 2-37.
  3. Gourbil M., Grandvuillemin A., Beyens M.N., Massy N., Gras V., D’Amico A. et al. Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals. Drug Saf. 2014; 37(4): 269-82.
  4. HeitJ.A. Epidemiology of venous thromboembolism. Nat. Rev. Cardiol. 2015; 12(8): 464-74. doi: 10.1038/nrcardio.2015.83.
  5. Профилактика венозных тромбоэмболических осложнений в акушерстве и гинекологии. Клинические рекомендации (протокол). Утв. М3 РФ 27 мая 2014 года №15-4102-3792. М.; 2014. 32с.
  6. Dinger J., Heinemann L.A., Kiihl-Habich D. The safety of a drospirenone-con- taining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years. Contraception. 2007; 75(5): 344-54.
  7. Hormonal Contraception and Risk of Venous Thromboembolism (VTE). Position statement. Society of Obstetricians and Gynaecologists of Canada. 19 February 2013. Available at: http://www.sogc.com/media/documents/med- HormonalContraceptioriVTE130219.pdf Accessed March 26, 2013.
  8. Petersen J.F., Bergholt T., Nielsen A.K., Paidas M.J., Lokkegaard E.C. Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy. Danish nationwide historical cohort 1995- 2009. Thromb. Haemost. 2014; 112(1): 73-8.
  9. SquizzatoA., Van Zaane B., Gerdes V.E., Biiller HR. The influence of pituitary, adrenal, and parathyroid hormones on hemostasis and thrombosis. Semin. Thromb. Hemost. 2011; 37(1): 41-8.
  10. Kyriakakis N., Lynch JAjjan R., Murray R.D. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications. Clin. Endocrinol. (Oxf). 2015; Mar 5. doi: 10.1111/cen.l2767. Available at: http://www.ncbi.nlm. nih.gov/pubmed/25753252 Accessed 15.07.2015.
  11. Wahlberg J., Tillmar L., Ekman B., Lindahl T.L., Landberg E. Effects of prolactin on platelet activation and blood clotting. Scand. J. Clin. Lab. Invest. 2013; 73(3): 221-8.
  12. van Zaane B., Squizzoto A., Reuwer A.Q., van Zanten A.P, Twickler M. T.-B., Dekkers O.M. et al. Prolactin and venous thrombosis indications for a novel risk factor? Arterioscler. Thromb. Vase. Biol. 2011; 31(3): 672-7.
  13. Rott H. Thrombotic risks of oral contraceptives. Curr. Opin. Obstet. Gynecol. 2012; 24(4): 235-40.
  14. Bitzer J. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur. J. Contracept. Reprod. Health Care. 2013; 18(3): 143-7.
  15. Bergendal A., Persson I., OdebergJ., Sundstrom A., Holmstrom M., Schulman S. et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet. Gynecol. 2014; 124(3): 600-9.
  16. Evans GSutton E.L. Oral contraception. Med. Clin. North Am. 2015; 99(3): 479-503.
  17. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ Referrals_document/cyproterone_ethinylestradiol_107i/European_ Commission_final_decision/WC500147176.pdf
  18. Хамошша М.Б., Зорина Е.А., Цапиева Е. О., Рукавцова Ю. С., Гончарова О.В. Комбинированные оральные контрацептивы и венозные тромбозы: современный взгляд на проблему. Доктор.Ру. 2013; 1:44-8
  19. Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции. ВОЗ, 4-еизд. 2009». М.; 2012. 242с
  20. Кесарево сечение. Показания, методы обезболивания, хирургическая техника, антибиотикопрофилактика, ведение послеоперационного периода. Клинические рекомендации (протокол). Утв. М3 РФ 27 мая 2014 года №15-4102-3185. М.; 2014. 44с
  21. Кровесберегающие технологии в акушерской практике. Клинические рекомендации (протокол). Утв. М3 РФ 29 мая 2014 года №15-4102-3798. М.; 2014. 42с
  22. Jensen T.B., Gerds T.A., Gron R., Bretler D.M., Schmiegelow M.D., Andersson C. et al. Risk factors for venous thromboembolism during pregnancy. Pharmacoepidemiol. Drug Saf. 2013; 22(12): 1283-91.
  23. Blondon M., Quon B.S., Harrington L.B., Bounameaux H, Smith N.L. Association between newborn birth weight and the risk of postpartum maternal venous thromboembolism: a population-based case-control study. Circulation. 2015; 131(17): 1471-6.
  24. Белокршшцкая T.E., Чарторижская H.H., Казанцева E.B., Фролова Н.И. Фетоплацентарная недостаточность. Чита: Читинская областная типография; 2009. 192с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies